SUN PHARMACEUTICAL INDUSTRIES

LIMITED

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company

headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and
active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest
pharma company in India and the fourth largest specialty generic pharmaceutical company in the
world, with total revenue of over US$4.5 billion as of June 2021. The products cater to a vast range of
therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopedic, diabetology,
gastroenterology, ophthalmology, nephrology, urology, dermatology, and gynecology, respiratory,
oncology, dental and nutritional. Its API products include Acamprosate Calcium, Alendronate Sodium,
Amifostine trihydrate, Budesonide, and Carvedilol

Sun Pharmaceuticals was founded by Dilip Shanghvi in 1983 in Vapi, Gujarat, with five products to
treat psychiatry ailments. Cardiology products were introduced in 1987 followed
by gastroenterology products in 1989. Today it is ranked No.1 by prescriptions with 9 different classes of
doctors in India and a market leader in cardiology, gastroenterology, diabetology, dermatology, urology,
and vitamins/minerals/nutrients

Sun Pharma was listed on the stock exchange in 1994 in an issue that oversubscribed 55 times. The
founding family continues to hold a majority stake in the company.

AREA OF BUSINESS IN INTERNATIONAL BUSINESS

 With global revenues of over US $ 4.5 billion, Sun
Pharma is the fourth largest specialty generic
pharmaceutical company in the world. We provide
high-quality, affordable medicines trusted by
healthcare professionals and patients in over 100
countries worldwide. Sun Pharma is also India’s
largest pharmaceutical company. Our global
presence is supported by over 40 manufacturing
facilities across six continents.
In the USA we have 30% of Revenue Share and
₹100,839 Million.
In India we have 31% of Revenue Share and
₹103,432 Million, Also No.1 Rank With 8.2%
Market Share
In Emerging Markets we have 18% of Revenue
Share and ₹57,834 Million and Leading
Pharmaceutical companies in the Emerging Market.
In Western Europe, Canada, Australia, Japan, New
Zealand it has a 15% Revenue Share and ₹48,191
Million

AREA OF OPERATION IN INTERNATIONAL

BUSINESS

In the US market, which contributes a significant

share of our revenues, we are the leader in the
generic dermatology segment. We have an
established presence in Europe and key high-
growth Emerging Markets (EM) like Italy,
Germany, Japan, South Korea, Australia, and
many others OPERATIONAL SHARES
Sun Pharma entered the US pharma market—the
world’s largest pharmaceutical market—in 1997
and has, since then, established its prominence in
the generics market. It is the tenth-largest 13% 22%
pharmaceutical company in the US generics 11%
market with the US business accounting for 30% 11%
22%
of annual consolidated sales. 11%
11%
Sun Pharma is one of the leading Indian
pharmaceutical companies in the emerging
markets. The Company sells its products in 80
global markets, with a focus on Romania, Russia,
South Africa, Brazil, Mexico, and other
complementary and affiliated markets. It has local
manufacturing units across Bangladesh, South
USA INDIA
Africa, Malaysia, Romania, Egypt, Nigeria, and
Russia, which provides increased flexibility in AUSTRALIA JAPAN
servicing these markets NEW ZEALAND WESTERN EUROPE
EMERGING COUNTRIES

AREA OF BUSINESS EXPANSION IN

INTERNATIONAL BUSINESS
 We have expanded our business apart from India
and USA to more than 100 countries across the
Globe including countries from Europe such as
Germany, Italy, and Romania. Also, we have our
Business operations in Russia, Japan, New
Zealand, South Africa, Brazil, Mexico,
Bangladesh Malaysia, Egypt, and Nigeria.
Such Expansion has help not only the company but
all our Global Consumers. During the Pandemic,
we were able to produce and provide vaccines,
medicines, and all those necessary precautionary
things not only to Indian Citizens but all Around
the Globe.
We are very proud to say despite many obstacles
and hardships. We are the company with a No.1
Ranking in India and No. 8 all around the Globe.

CHALLENGES FACED BY
SUN PHARMACEUTICAL COMPANY

Inordinate delay in the resolution of USFDA

issues at its key plant at Halol.
Inorganic growth could not help the company
dodge the sectoral headwinds.
One of the Indian companies to face price
collusion charges in the US.
Promoter investment in non-core businesses like
solar.